Literature DB >> 31016540

Efficacy and safety of selective COX-2 inhibitors for pain management after third molar removal: a meta-analysis of randomized clinical trials.

Albert González-Barnadas1, Octavi Camps-Font1, Pablo Martín-Fatás1, Rui Figueiredo2,3, Cosme Gay-Escoda1,4, Eduard Valmaseda-Castellón1.   

Abstract

OBJECTIVES: To compare selective COX-2 inhibitors with ibuprofen in terms of analgesia, rescue medication consumption, and adverse effects after impacted third molar removal.
MATERIALS AND METHODS: Electronic databases were searched. Single dose, double-blind, randomized, and controlled clinical trials comparing the analgesic effect of a selective COX-2 inhibitor versus at least one active control group using ibuprofen after impacted third molar removal were selected.
RESULTS: Twelve studies were included for the qualitative synthesis and eight were included in the meta-analysis. No statistically significant differences were found between selective COX-2 inhibitors and ibuprofen in terms of pain relief after 6, 8, and 12 h. Rescue analgesia use after 24 h was significantly greater in the ibuprofen group than in the selective COX-2 inhibitor group. There were no statistically significant differences in the number of patients presenting one or more adverse events between the two groups, though ibuprofen intake was related with more nausea and vomiting.
CONCLUSIONS: No statistically significant differences were found in terms of pain relief 6, 8, and 12 h post-medication between selective COX-2 inhibitors and ibuprofen following totally or partially impacted third molar removal. The patients who consumed selective COX-2 inhibitors needed less rescue analgesia after 24 h. The occurrence of one or more adverse events was similar in both groups, though patients who consumed ibuprofen had more nausea and vomiting. CLINICAL RELEVANCE: COX-2 inhibitors could be considered a suitable alternative to ibuprofen for pain relief after third molar extraction in patients at risk of developing nausea and vomiting. Also, COX-2 inhibitors seem to slightly reduce the need of rescue medication consumption.

Entities:  

Keywords:  Analgesics; COX-2 inhibitors; Ibuprofen; Pain relief; Third molars

Mesh:

Substances:

Year:  2019        PMID: 31016540     DOI: 10.1007/s00784-019-02910-3

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  30 in total

Review 1.  Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis.

Authors:  Patompong Ungprasert; Narat Srivali; Wonngarm Kittanamongkolchai
Journal:  Eur J Intern Med       Date:  2015-10-01       Impact factor: 4.487

Review 2.  Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials.

Authors:  Ricardo Carvalho Lopes Silva; Rachel Riera; Humberto Saconato
Journal:  Sao Paulo Med J       Date:  2011       Impact factor: 1.044

3.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

4.  Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.

Authors:  R De Vecchis; C Baldi; G Di Biase; C Ariano; C Cioppa; A Giasi; L Valente; S Cantatrione
Journal:  Minerva Cardioangiol       Date:  2014-07-16       Impact factor: 1.347

Review 5.  Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

Authors:  Patricia McGettigan; David Henry
Journal:  JAMA       Date:  2006-09-12       Impact factor: 56.272

6.  Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: verification from independent data.

Authors:  A Moore; H McQuay; D Gavaghan
Journal:  Pain       Date:  1997-01       Impact factor: 6.961

Review 7.  Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis.

Authors:  Saharat Jarupongprapa; Prapassorn Ussavasodhi; Wanruchada Katchamart
Journal:  J Gastroenterol       Date:  2012-12-04       Impact factor: 7.527

8.  Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials.

Authors:  Andrew Moore; Geoffrey Makinson; Chunming Li
Journal:  Arthritis Res Ther       Date:  2013-01-08       Impact factor: 5.156

9.  Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.

Authors:  Isla S Mackenzie; Li Wei; Thomas M Macdonald
Journal:  Eur J Clin Pharmacol       Date:  2012-06-26       Impact factor: 2.953

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

View more
  3 in total

Review 1.  Chemically Diverse and Biologically Active Secondary Metabolites from Marine Phylum chlorophyta.

Authors:  Sayed Asmat Ali Shah; Syed Shams Ul Hassan; Simona Bungau; Yongsheng Si; Haiwei Xu; Md Habibur Rahman; Tapan Behl; Daniela Gitea; Flavia-Maria Pavel; Raluca Anca Corb Aron; Bianca Pasca; Sebastian Nemeth
Journal:  Mar Drugs       Date:  2020-09-26       Impact factor: 5.118

Review 2.  Analgesic Efficacy of Etoricoxib following Third Molar Surgery: A Meta-analysis.

Authors:  Lorenzo Franco-de la Torre; Diana Laura Franco-González; Lorena Michele Brennan-Bourdon; Nelly Molina-Frechero; Ángel Josabad Alonso-Castro; Mario Alberto Isiordia-Espinoza
Journal:  Behav Neurol       Date:  2021-09-08       Impact factor: 3.342

3.  Identification of New Targets and the Virtual Screening of Lignans against Alzheimer's Disease.

Authors:  Mayara Dos Santos Maia; Gabriela Cristina Soares Rodrigues; Natália Ferreira de Sousa; Marcus Tullius Scotti; Luciana Scotti; Francisco Jaime B Mendonça-Junior
Journal:  Oxid Med Cell Longev       Date:  2020-08-15       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.